Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207274 | 1.00 | PKM (0.39) | PKMTP53SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL31164061 | 0.86 | PKM (0.38) | PKMSMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL26180811 | 0.86 | PKM (0.38) | PKMSMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL20037497 | 0.85 | PKM (0.37) | PKMSMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL26180900 | 0.85 | PKM (0.40) | PKMSMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL26180903 | 0.85 | PKM (0.40) | PKMSMN1; SMN2LMNAALDH1A1CYP1A2 | |
| SCHEMBL20207266 | 0.85 | SMN1; SMN2 (0.37) | PKMTP53SMN1; SMN2NTRK1LMNA | |
| SCHEMBL20037602 | 0.85 | HASPIN (0.37) | TP53SMN1; SMN2TSHRNTRK1LMNA | |
| SCHEMBL20203573 | 0.85 | SMN1; SMN2 (0.37) | PKMTP53SMN1; SMN2NTRK1LMNA | |
| SCHEMBL21402723 | 0.84 | PKM (0.37) | PKMSMN1; SMN2LMNAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4450501-A1 | CDK9 INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3546456-B1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3546456-B1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20210276997-A1 | CRYSTAL OF PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20210276997-A1 | CRYSTAL OF PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| EP-3546456-A1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| EP-3546456-A1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| WO-2018097295-A1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PKM 610/4885TP53 220/4885SMN1; SMN2 1690/4885 |
| US-20210276997-A1 | CRYSTAL OF PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | CDK6, CDK4, CDKL4 | PKM 790/4885TP53 1236/4885SMN1; SMN2 3386/4885 |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | PKM 372/4885TP53 1042/4885SMN1; SMN2 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.